Literature DB >> 2612733

Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells.

I Touitou1, V Cavaillès, M Garcia, A Defrenne, H Rochefort.   

Abstract

The precursor of cathepsin D, a lysosomal acidic protease, is secreted by human breast cancer cells, where its synthesis is specifically induced by estrogens and growth factors. In this study, we investigated the hormonal regulation of cathepsin D and its mRNA in uterine cells. In the Ishikawa endometrial cancer cell line, epidermal growth factor (EGF) increased the level of cathepsin D and its mRNA 2- to 3-fold. Although expression of the transiently transfected estrogen-responsive recombinant (Vit. tk. CAT) and the endogenous progesterone receptor was markedly increased by estradiol in Ishikawa cells, estradiol did not alter the level of cathepsin D or its mRNA. The progestin R5020 induced the expression of the LTR sp65 CAT, which contains the progesterone-responsive element of the MMTV but it too was without effect on cathepsin D. By contrast, the expression of cathepsin D gene, in normal rat uterus, was increased by R5020 but not by estradiol. We conclude that cathepsin D gene expression is regulated differently by sex steroid hormones in endometrial and breast cancer cell lines, whereas it is similarly induced by EGF in these cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2612733     DOI: 10.1016/0303-7207(89)90035-x

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  11 in total

1.  Proteome differences between male and female fetal cells in amniotic fluid.

Authors:  Chih-Ping Chen; Tzu-Chia Lai; Schu-Rern Chern; Sheng-Hsiang Li; Hsiu-Chuan Chou; Yi-Wen Chen; Szu-Ting Lin; Ying-Chieh Lu; Chieh-Lin Wu; Ji-Min Li; Hong-Lin Chan
Journal:  OMICS       Date:  2012-03-09

2.  Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy.

Authors:  R Medina; S S Wing; A L Goldberg
Journal:  Biochem J       Date:  1995-05-01       Impact factor: 3.857

Review 3.  Cathepsin D in breast cancer.

Authors:  H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1990-07       Impact factor: 4.872

4.  Western blotting and isoform analysis of cathepsin D from normal and malignant human breast cell lines.

Authors:  L D Laury-Kleintop; E C Coronel; M K Lange; T Tachovsky; S Longo; S Tucker; J A Alhadeff
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

Review 5.  Evaluation of cathepsin D as a prognostic factor in breast cancer.

Authors:  P M Ravdin
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells.

Authors:  V Cavaillès; P Augereau; H Rochefort
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

7.  Cathepsin D immunoreactivity in ovarian cancer: correlation with prognostic factors.

Authors:  P Athanassiadou; V Sakellariou; E Petrakakou; P Athanassiades; C Zerva; A Liossi; S Michalas
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 8.  Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

Authors:  Gaetano Leto; Francesca M Tumminello; Marilena Crescimanno; Carla Flandina; Nicola Gebbia
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  Lysosomal protease cathepsin D is a prognostic marker in endometrial cancer.

Authors:  A Lösch; P Kohlberger; G Gitsch; A Kaider; G Breitenecker; C Kainz
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

10.  Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.

Authors:  O Falcón; R Chirino; L León; A López-Bonilla; S Torres; L Fernández; J A García-Hernández; P F Valerón; J C Díaz-Chico
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.